Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated with irreversible cardiac cell injury, and it is typically caused by anthracyclines and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and more targeted drugs, and it is associated with reversible myocardial dysfunction. Therefore, patients undergoing anti-cancer treatments should be closely monitored, and patients at risk of CTX should be identified before beginning treatment to reduce CTX-related morbidity. Future Directions: Genetic profiling of clinical risk factors and an integrated approach using molecular, imaging, and clinical data may allow the recognition of patients who are at a high risk of developing chemotherapy-related CTX, and it may suggest methodologies to limit damage in a wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer treatments is a very active field of research. Further investigations will be necessary to uncover the hallmarks of cancer from a redox perspective and to develop more efficacious antineoplastic therapies that also spare the cardiovascular system.

Tocchetti, C., Cadeddu, C., Di Lisi, D., Femminò, S., Madonna, R., Mele, D., et al. (2019). From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview. ANTIOXIDANTS & REDOX SIGNALING, 30(18), 2110-2153 [10.1089/ars.2016.6930].

From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview

DI LISI, Daniela;NOVO, Giuseppina;
2019-01-01

Abstract

Significance: Antineoplastic therapies have significantly improved the prognosis of oncology patients. However, these treatments can bring to a higher incidence of side-effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is, therefore, crucial for effective cardioprotection, without compromising the efficacy of anti-cancer treatments. Critical Issues: CTX can occur within a few days or many years after treatment. Type I CTX is associated with irreversible cardiac cell injury, and it is typically caused by anthracyclines and traditional chemotherapeutics. Type II CTX is generally caused by novel biologics and more targeted drugs, and it is associated with reversible myocardial dysfunction. Therefore, patients undergoing anti-cancer treatments should be closely monitored, and patients at risk of CTX should be identified before beginning treatment to reduce CTX-related morbidity. Future Directions: Genetic profiling of clinical risk factors and an integrated approach using molecular, imaging, and clinical data may allow the recognition of patients who are at a high risk of developing chemotherapy-related CTX, and it may suggest methodologies to limit damage in a wider range of patients. The involvement of redox mechanisms in cancer biology and anticancer treatments is a very active field of research. Further investigations will be necessary to uncover the hallmarks of cancer from a redox perspective and to develop more efficacious antineoplastic therapies that also spare the cardiovascular system.
2019
Tocchetti, C., Cadeddu, C., Di Lisi, D., Femminò, S., Madonna, R., Mele, D., et al. (2019). From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: A translational overview. ANTIOXIDANTS & REDOX SIGNALING, 30(18), 2110-2153 [10.1089/ars.2016.6930].
File in questo prodotto:
File Dimensione Formato  
tocchetti2017.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 3.28 MB
Formato Adobe PDF
3.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
ars.2016.6930.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 5.68 MB
Formato Adobe PDF
5.68 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/238486
Citazioni
  • ???jsp.display-item.citation.pmc??? 42
  • Scopus 100
  • ???jsp.display-item.citation.isi??? 85
social impact